Bilaketaren emaitzak - John F. Kokai–Kun

  • Erakusten 1 - 16 emaitzak -- 16
Findu emaitzak
  1. 1
    Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of <i>Staphylococcus aureus</i>

    Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of <i>Staphylococcus aureus</i> nork Caroline M. Kusuma, John F. Kokai–Kun

    Argitaratua 2005
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Deletion analysis of the Clostridium perfringens enterotoxin

    Deletion analysis of the Clostridium perfringens enterotoxin nork John F. Kokai–Kun, Bruce A. McClane

    Argitaratua 1997
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model

    Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model nork John F. Kokai–Kun, Tanya Chanturiya, J J Mond

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice

    Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice nork John F. Kokai–Kun, Tanya Chanturiya, James J. Mond

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Lysostaphin Cream Eradicates <i>Staphylococcus aureus</i> Nasal Colonization in a Cotton Rat Model

    Lysostaphin Cream Eradicates <i>Staphylococcus aureus</i> Nasal Colonization in a Cotton Rat Model nork John F. Kokai–Kun, S. M. Walsh, Tanya Chanturiya, James J. Mond

    Argitaratua 2003
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Lysostaphin Disrupts <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> Biofilms on Artificial Surfaces

    Lysostaphin Disrupts <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> Biofilms on Artificial Surfaces nork Julie A. Wu, Caroline M. Kusuma, James J. Mond, John F. Kokai–Kun

    Argitaratua 2003
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    COVID-19 vaccine platforms: Delivering on a promise?

    COVID-19 vaccine platforms: Delivering on a promise? nork Mark Verdecia, John F. Kokai–Kun, Maura Kibbey, Sarita Acharya, Jaap Venema, Fouad Atouf

    Argitaratua 2021
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Comparison of Western immunoblots and gene detection assays for identification of potentially enterotoxigenic isolates of Clostridium perfringens

    Comparison of Western immunoblots and gene detection assays for identification of potentially enterotoxigenic isolates of Clostridium perfringens nork John F. Kokai–Kun, J. Glenn Songer, John R. Czeczulin, Fei Chen, Bruce A. McClane

    Argitaratua 1994
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in<i>Staphylococcus aureus</i>

    Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in... nork Kate Cosgrove, Graham Coutts, Ing‐Marie Jonsson, Andrej Tarkowski, John F. Kokai–Kun, James J. Mond, Simon J. Foster

    Argitaratua 2006
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

    Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial nork John F. Kokai–Kun, Tracey Roberts, Olivia Coughlin, Chenxiong Le, Heidi Whalen, Ralph W. Stevenson, Vincent J. Wacher, Joseph Sliman

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    The Staphylococcus aureus Surface Protein IsdA Mediates Resistance to Innate Defenses of Human Skin

    The Staphylococcus aureus Surface Protein IsdA Mediates Resistance to Innate Defenses of Human Skin nork Simon R. Clarke, Ramlan Mohamed, Bian Li, Alexander F. Routh, John F. Kokai–Kun, James J. Mond, Andrej Tarkowski, Simon J. Foster

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of <i>Staphylococcus aureus</i>

    Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of <i>Staphylococcus aureus</i> nork Melanie R. Stapleton, Malcolm J. Horsburgh, Emma J. Hayhurst, Lynda Wright, Ing‐Marie Jonsson, Andrej Tarkowski, John F. Kokai–Kun, James J. Mond, Simon J. Foster

    Argitaratua 2007
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

    The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies nork John F. Kokai–Kun, Tracey Roberts, Olivia Coughlin, Éric Sicard, Marianne Rufiange, Richard N. Fedorak, Christian Carter, Marijke H. Adams, James Longstreth, Heidi Whalen, Joseph Sliman

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates

    Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevent... nork Leonard E. Weisman, Helen Thackray, Joseph A. Garcia‐Prats, Mirjana Nesin, Joseph H. Schneider, Jennifer Fretz, John F. Kokai–Kun, James J. Mond, William G. Kramer, G. Fischer

    Argitaratua 2009
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection

    Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection nork Michael Kaleko, J. Andrew Bristol, Steven Hubert, Todd B. Parsley, Giovanni Widmer, Saul Tzipori, Poorani Subramanian, Nur A. Hasan, Perrti Koski, John F. Kokai–Kun, Joseph Sliman, Annie Jones, Sheila Connelly

    Argitaratua 2016
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Identification of In Vivo–Expressed Antigens of<i>Staphylococcus aureus</i>and Their Use in Vaccinations for Protection against Nasal Carriage

    Identification of In Vivo–Expressed Antigens of<i>Staphylococcus aureus</i>and Their Use in Vaccinations for Protection against Nasal Carriage nork Simon R. Clarke, Kirsten J. Brummell, Malcolm J. Horsburgh, Philip W. McDowell, Sharifah Aminah Syed Mohamad, Melanie R. Stapleton, Jorge Luis Arroyo-Acevedo, Robert C. Read, Nicholas P. J. Day, Sharon J. Peacock, James J. Mond, John F. Kokai–Kun, Simon J. Foster

    Argitaratua 2006
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: